Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

Transplantation

Volumn 80, Issue 9, 2005, Pages 1212-1219

  Thaunat, Olivier ^a   Beaumont, Carole ^b   Chatenoud, Lucienne ^a   Lechaton, Sophie ^a   Mamzer Bruneel, Marie France ^a   Varet, Bruno ^a   Kreis, Henri ^a   Morelon, Emmanuel ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Anemia; Inflammation; Sirolimus

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOKINE; ERYTHROPOIETIN; FIBRINOGEN; HEMOGLOBIN; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; IRON BLOOD LEVEL; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LINEAR REGRESSION ANALYSIS; MALE; MICROCYTIC ANEMIA; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 28544432476     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000179106.07382.6a     Document Type: Article

References (27)

1. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72(5): 777.
2. Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17(6): 660.
3. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66(8): 1040.
4. Ikonen TS, Briffa N, Gummert JF, et al. Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys. Transplantation 2000; 70(3): 420.
5. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49(1): 209.
6. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69(10): 2085.
7. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35 (3 Suppl): 52S.
8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255.
9. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72(5): 787.
10. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3(7): 835.
11. Jaster R, Bittorf T, Klinken SP, Brock J. Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 1996; 51(9): 1181.
12. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003; 329 (1-2): 9.
13. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22(2): 169.
14. Neff GW, Montalbano M, Slapak-Green G, et al. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003; 9(5): 477.
15. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989; 61(3): 319.
16. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995; 85(4): 989.
17. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002; 100(2): 474.
18. Davis D, Charles PJ, Potter A, et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36(9): 950.
19. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113(9): 1271.
20. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002; 99(7): 4596.
21. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001; 98(15): 8780.
22. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163(2): 316.
23. Fijen JW, Kobold AC, de Boer P, et al. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Intern Med 2000; 11(2): 89.
24. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174(5): 1209.
25. Zingarelli B, Yang Z, Hake PW, et al. Absence of endogenous interleukin 10 enhances early stress response during post-ischaemic injury in mice intestine. Gut 2001; 48(5): 610.
26. Jorgensen PF, Wang JE, Almlof M, et al. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 2001; 53(2): 184.
27. Foey A, Green P, Foxwell B, et al. Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res 2002; 4(1): 64.